Cellspan Esophageal Implant (CEI)

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company with a mission to regenerate damaged organ tissue using a patient's own stem cells and a proprietary bioabsorbable scaffold. Its key achievement is the FDA approval of an IND and the initiation of a Phase 1 clinical trial for its Cellspan Esophageal Implant, following a landmark first-in-human case at the Mayo Clinic. The company's strategy focuses on addressing severe, unmet medical needs in hollow organ repair, starting with esophageal atresia and cancer, leveraging a platform technology with potential applications in tracheal and bronchial regeneration.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company with a mission to regenerate damaged organ tissue using a patient's own stem cells and a proprietary bioabsorbable scaffold. Its key achievement is the FDA approval of an IND and the initiation of a Phase 1 clinical trial for its Cellspan Esophageal Implant, following a landmark first-in-human case at the Mayo Clinic. The company's strategy focuses on addressing severe, unmet medical needs in hollow organ repair, starting with esophageal atresia and cancer, leveraging a platform technology with potential applications in tracheal and bronchial regeneration.

Therapeutic Areas